"Translational Neuroimaging: Tools for CNS Drug Discovery, Development and Treatment" combines the experience of academic, clinical and industrial neuroimagers in a unique collaborative approach to provide an integrated perspective of the use of small animal and human brain imaging in developing and validating translational models and biomarkers for the study and treatment of neuropsychiatric disorders. "Translational Neuroimaging: Tools for CNS Drug Discovery, Development and Treatment" examines the translational role of neuroimaging in model development from preclinical animal models, to human experimental medicine, and finally to clinical studies. The focus of this book is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This book covers methodical issues in human and animal neuroimaging translational research as well as detailed applied examples of the use of neuroimaging in neuropsychiatric disorders and the development of drugs for their treatment. Offering an accompanying website with illustrations and text available for further knowledge and presentations, "Translational Neuroimaging: Tools for CNS Drug Discovery, Development and Treatment" appeals to non-clinical and clinical neuroscientists working in and studying neuropsychiatric disorders and their treatment as well as providing the novice researcher or researcher outside of his/her expertise the opportunity to understand the background of translational research and the use of imaging in this field.
Provides a background to translational research and the use of brain imaging in neuropsychiatric disordersCritical discussion of the potential and limitations of neuroimaging as a translational tool for identifying and validating biomarkersIdentifies cross species neurosystems and common endpoints necessary to help accelerate CNS drug discovery and development for the treatment of neuropsychiatric disordersFeatures an accompanying website with additional images and text

Obesity is an epidemic with enormous health, economic and social burdens. Current drugs for obesity treatment are far from ideal in terms of efficacy and side effects. Reviews in this volume of Progress in Molecular Biology and Translational Science summarize current status in studies of a number of G protein-coupled receptors that were shown to be promising targets for obesity treatments. Some of these receptors also cause monogenic obesity in humans.
Subject matter: obesity is an epidemic and G protein-coupled receptors are promising drug targets, with significant potential as new anti-obesity drugs.

Chapters are written by leading experts.

This third edition volume expands on the previous editions both by presenting more detailed protocols for the techniques described in the first and second editions of High Throughput Screening: Methods and Protocols and by covering important new procedures. The first chapter of this book provides an overview of important assay development techniques, while the rest of the chapters detail how to develop and execute screens at whatever throughput the user needs. Some chapter examples are: structure-based virtual screening, high throughput screening using mass spectrometry, identification of state-dependent blockers for voltage gated calcium channels, bioluminescence resonance energy transfer platform to monitor protein-protein interactions in live cells, high throughput flow cytometry, and application of imaging-based assays in microplate formats for high content screening. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting edge and thorough, High Throughput Screening: Methods and Protocols, Third Edition, is a valuable resource for anyone who is interested in HTS research.

The concept of immunotherapy was in infancy when the first edition was written; since then, major advances have been made, not only with several prominent clinical trials, but also with the approval of cell-based therapy by the FDA for the treatment of cancer in 2010. These events resulted in a gradually narrowing gap between early scientific knowledge and the late development of immune-based therapies. Consequently, the significance and magnitude of these advances warranted a revision of this contribution; this revised edition will provide a deeper understanding of the recent advances and discoveries related to the function of the immune response and their applications in the development of novel therapies to treat human diseases. Some of the key discoveries during the past five years include: the identification of the new subsets of helper T cells; new cytokines and their networks; and novel signal transduction mechanisms. For example, the identification of TH17 subset of helper T cells, in addition to TH1 and TH2 cells, not only advanced our understanding of the function of the basic immune response, but also raised our awareness of the possible etiology and pathogenesis of diseases such as allergy, asthma, rheumatoid arthritis, and other auto-immune/immune system based diseases. The newly identified powerful cytokine networks, that regulate both innate and acquired immune responses, emerged as a result of the finding of new cell types such as innate lymphoid cells and iNKT. Identification of the novel cytokines and their networks has advanced our knowledge of the mechanisms involved in the maintenance of tissue homeostasis, including inflammation and tissue repair during stress and injury. The development of HIV vaccines has also seen dramatic changes over the last few years. There has been a shift from a sole focus on T cell vaccines to a holistic approach that pertains to the induction of both humoral and cellular elements. This entails the induction of antibodies - both binding and neutralizing - to prevent infection. The cellular vaccination produces a safety net of CD8+ T-cell responses to suppress the replication of the virus in the infected patients, and both of the effector arms are aided by helper T cells. From the perspective of clinical applications, significant advances have also been made in: oral immunotherapy for allergic disease, the possible treatment of HIV infection, the development of new monoclonal antibodies and their fragments to treat human diseases, and immune cell based therapies for cancer.

Psychopharmacology is a dominant treatment in child and adolescent psychiatry with proven benefits to young patients. The authors present topics related to PSYCHOPHARMACOLOGY ISSUES: Ethical issues, Treatment planning, Side effects, Neural correlates, and Pharmacogenomics. They address DRUGS FOR SPECIFIC DISEASES: Anxiety, Depression, Eating disorders, Sleep disorders, Psychosis and Schizophrenia, High-risk for bilpolar and schizophrenia, Bipolar, ADHD, and Autism. Each topic presents an Overview of the Disease or Issue, Empirical evidence for ethical issues, Treatment summaries that include dose ranges, side effects, contraindications, and how the drugs are used specifically for a disorder. Treatment in the presence of co-morbid conditions, Long-term evidence, and Conclusions and Future directions complete the presentations. Clinical vignettes are provided that exemplify the main points of the topic.

The book will provide an exhaustive and clear explanation of how Statistics, Mathematics and Informatics have been used in cancer research, and seeks to help cancer researchers in achieving their objectives. To do so, state-of-the-art Biostatistics, Biomathematics and Bioinformatics methods will be described and discussed in detail through illustrative and capital examples taken from cancer research work already published. The book will provide a guide for cancer researchers in using Statistics, Mathematics and Informatics, clarifying the contribution of these logical sciences to the study of cancer, thoroughly explaining their procedures and methods, and providing criteria to their appropriate use.

1. Gene Therapy.- Asthma.- 2. Genetics of Asthma.- 3. Transcription Factors and Inflammatory Lung Disease.- 4. Regulation of the Cytokine Gene Cluster on Chromosome 5q.- 5. Cytokine Expression in Asthma.- 6. ?-Adrenoceptors.- 7. Regulation of Eosinophil Migration.- 8. Proteinase Allergens of House Dust Mites: Molecular Biology, Biochemistry and Possible Functional Significance of Their Enzyme Activity.- Cancer.- 9. Gene Expression in Lung Cancer.- 10. Gene Therapy for Cancer: Prospects for the Treatment of Lung Tumours.

"Annual Reports in Medicinal Chemistry "provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.
Timely and critical reviews of important topics in medicinal chemistry

This book brings together reviews from international experts who are exploring the biological activities of nanomaterials for medical applications or to better understand nanotoxicity. Topics include but are not limited to the following: 1) mechanistic understanding of nanostructure-bioactivity relationships; 2) the regulation of nanoparticles' bioactivity by means of chemical modification; 3) the new methodologies and standard methods used to assess nanoparticles' bioactivity; 4) the mechanisms involved in nanoparticle-biomolecule interactions and nanoparticle-cell interactions; and 5) biomedical applications of nanotechnology. The book will be a valuable resource for a broad readership in various subfields of chemical science, engineering, biology, environment, and medicine.

This issue of Endocrinology Clinics brings the reader up do date on the current standards and important advances in insulin therapy.? The following clinical topics are discussed: types of insulins, including new insulins; goals of therapy; pathophysiology of, and insulin treatment in type1 and type 2 diabetes mellitus; pumps and glucose sensors; alternative insulin delivery; patient and provider insulin resistance; inpatient insulin therapy; insulin therapy in pregnancy; and pediatric insulin therapy.

This new volume of "Advances in Pharmacology" explores the current concepts in drug metabolism and toxicology. Chapters cover the Keap1-Nrf2 cell defense pathway, animal models of drug-induced idiosyncratic toxicity and the use of human embryonic and induced pluripotent stem cells for modeling metabolism and toxicity. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike.
Explores the current concepts in drug metabolism and toxicology Chapters cover such areas as the Keap1-Nrf2 cell defense pathway, animal models of drug-induced idiosyncratic toxicity and the use of human embryonic and induced pluripotent stem cells for modeling metabolism and toxicityAn essential resource for pharmacologists, immunologists and biochemists alike

"TherapeuticDrug Monitoring: Newer Drugs andBiomarkers"features timely topics such as the monitoring of classical and newer drugs, pharmacogenomics and the application of biomarkers in therapeutic drug monitoring. This reference also discusses the limitations of current commercially available immunoassays for therapeutic monitoring. It presentsnew and sophisticated techniques used for proper determination of blood levels and the clinical utility of therapeutic drug monitoring of contemporary drugs. Written by leading international experts and geared toward clinical pathologists, toxicologists, clinical chemists, laboratory professionals and physicians, this book is an essential resource on the current practice of therapeutic drug monitoring in improving patient safety.

Includes both the technical and clinical issues associated with therapeutic drug monitoring.

Discusses theutility of therapeutic drug monitoring of newer drugs such as antiretroviral agents, anticonvulsants, antidepressants etc.

Provides up-to-date information onissues inpharmacogenomics and personalized medicine with emphasis on therapy with warfarin, certain anticancer drugs and antidepressants.

Covers important content on thelimitations of commercially available immunoassays (chemical tests) for therapeutic drug monitoring and additional analytical techniques. "

This volume assembles the leading aggression researchers both at the preclinical and clinical level. They review the current state of knowledge about neural mechanisms of aggressive behavior and point to the need for innovative methodologies to further our understanding of this greatly understudied set of behaviors.

The misfolding and aggregation of specific proteins is an early and obligatory event in many of the age-related neurodegenerative diseases of humans. The initial cause of this pathogenic cascade and the means whereby disease spreads through the nervous system, remain uncertain. A recent surge of research, first instigated by pathologic similarities between prion disease and Alzheimer s disease, increasingly implicates the conversion of disease-specific proteins into an aggregate-prone b-sheet-rich state as the prime mover of the neurodegenerative process. This prion-like corruptive protein templating or seeding now characterizes such clinically and etiologically diverse neurological disorders as Alzheimers disease, Parkinson s disease, Huntington s disease, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Understanding the misfolding, aggregation, trafficking and pathogenicity of the affected proteins could therefore reveal universal pathomechanistic principles for some of the most devastating and intractable human brain disorders. It is time to accept that the prion concept is no longer confined to prionoses but is a promising concept for the understanding and treatment of a remarkable variety of diseases that afflict primarily our aging society. "

This volume presents key topics of current interest with regard to several pathophysiological conditions including (a) the basic and clinical aspects of bradykinin receptor antagonists, (b) the kallikrein-kinin pathways in hypertension and diabetes, (c) tissue kallikrein-kinin therapy for hypertension and organ damage, (d) the renal (tissue) kallikrein-kinin system in the kidney and novel potential drugs for salt-sensitive hypertension, (e) the kallikrein-kinin system in diabetes retinopathy and (f) genetic manipulation and genetic variation of the kallikrein-kinin system and their impacts on cardiovascular and renal disease. Written by internationally reputed scientists, the book provides an essential overview of the latest developments in the field of kinin research, making it a valuable asset for endocrinologists, nephrologists, cardiologists, pharmacologists, physiologists, ophthalmologists and rheumatologists. Furthermore, it is also intended for postgraduate students in the fields of medicine, pharmacy, physiology and pharmacology and those working at research organizations.

Dr. Spitzer has created an issue devoted to the evidence-based pharmacologic care of the neonate. The issue opens with an important article on? A Quality Improvement Approach to Modifying Medication Use in the NICU. The expert authors he has secured have contributed articles in the areas of therapeutic drug monitoring, off-label use of medications in the NICU, antenatal and post-natal corticosteroids, antibiotics, antifungals, and antivirals, as well as bronchodilators and nitric oxide. Other articles also present evidence-based use of oxygen, dopamine, anesthetics and analgesics, and erythropoetin.

"Clinical Pharmacology During Pregnancy" is written for clinicians, physicians, midwives, nurses, pharmacists and other medical professionals directly involved in the care of women during pregnancy. This book focuses on the impact of pregnancy on drug disposition and also includes coverage of treatments for diseases of specific body systems as well as essential content on dosing and efficacy.

The broad range of this book encompasses analgesics, antiasthmatics, antidepressants, heart and circulatory drugs, vitamins and herbal supplements, and more. Topics in chemotherapy and substance abuse are covered, as are research issues, including clinical trial design and ethical considerations.
Uses an evidence-based approach for therapeutics during pregnancyIncludes a summary of specific medications by indication with up-to-date information on dosing and efficacy in pregnancy for the given indicationIncludes a companion website containing support materials for professional or continuing education courses in OB pharmacology

The "Side Effects of Drugs Annual" was first published in 1977. It has been continually published since then as a yearly update to the voluminous encyclopedia, "Meyler's Side Effects of Drugs." Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of adverse drug reactions and interactions. An international team of specialists has contributed to the informative Annual by critically interpreting it and by pointing to whatever is misleading.
Provides a critical yearly survey of new data and trendsSpecial reviews in this Annual include, among other topics, epidemiology of the use of ecstasy, paracetamol and the risk of asthma, combination vaccines/multiple immunizations, interactions of herbal medicines with warfarin, and tyrosine kinase inhibitors